Rheologics to Demonstrate a More Accurate Blood Viscosity Test at the American Heart...

"Rheologics' focus is to provide the medical community with a better understanding of the importance of blood viscosity, and the tools for better utilizing its measurement in the prevention and treatment of atherosclerosis," noted company founder and CEO Kenneth R. Kensey, M.D. "The AHA conference is an excellent venue for giving healthcare providers and researchers a hands-on opportunity to test the Kensey Rheolog, a device we hope will ultimately improve the quality of life for millions of people worldwide."

Unlike standard viscometer devices, the Kensey Rheolog requires a minimal blood sample and returns individual test results in less than five minutes. Conference attendees can watch a demonstration or actually test their blood viscosity levels at the Rheologics' booth throughout the event.

About Rheologics, Inc.

Since 1997, Rheologics, Inc. (formerly known as Visco Technologies) has pioneered a new standard of care in the prevention and treatment of heart disease and stroke. Supplementing the existing understanding of the risk factors for these diseases, Rheologics' mission is to complete the picture by focusing on the emerging field of hemorheology -- the study of the dynamics of blood flow and its impact on vascular-related diseases. The company is providing the medical community with an innovative and more accurate blood viscosity measurement technology to be used at the patient point-of-care and in the development of new cardiac and stroke drug compounds. Its breakthrough product, the Kensey Rheolog(TM), is the industry's first easy-to-use viscometer for measuring the biophysical properties of unadulterated, circulating blood -- improving diagnostic research and reporting accuracy. The company is headquartered in Exton, Pa. For more information, please call 800/969-2585 or visit the company web site at www.rheologics.com.